Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264442 | 0.81 | — | — | |
| SCHEMBL328794 | 0.76 | TDP1 (0.40) | AHRAPEX1 | |
| SCHEMBL28651893 | 0.70 | MAPT (0.43) | APEX1 | |
| SCHEMBL10831166 | 0.69 | P2RX7 (0.32) | — | |
| SCHEMBL1304745 | 0.69 | CYP2A6 (0.37) | AHR | |
| SCHEMBL29682017 | 0.69 | CYP2A6 (0.37) | AHR | |
| SCHEMBL29702023 | 0.69 | GABRA1 (0.48) | AHR | |
| SCHEMBL30861902 | 0.69 | AHR (0.35) | AHR | |
| SCHEMBL18135450 | 0.69 | GABRA1 (0.48) | AHR | |
| SCHEMBL11578830 | 0.68 | APEX1 (0.31) | APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2202864-A | — | — | None | — | — | JP | disclosed |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2024-07-04 | — | — | US | disclosed |
| US-20230125359-A1 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-04-27 | — | — | US | disclosed |
| US-9334295-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-9334295-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2015-02-12 | — | — | US | disclosed |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2015-02-12 | — | — | US | disclosed |
| US-8927526-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-8927526-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2013-10-24 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481742-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | KANEQ PHARMA INC. (CA) | 2012-07-12 | — | — | US | disclosed |
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | KANEQ PHARMA INC. (CA) | 2012-07-12 | — | — | US | disclosed |
| US-8168815-B2 | Fused aromatic PTP-1B inhibitors | KANEQ PHARMA INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | KANEQ PHARMA INC. (CA) | 2010-01-28 | — | — | US | disclosed |
| JP-H02202864-A | 2,3-DICYANO-6-NAPHTHYLMETHANOL DERIVATIVE AND PRODUCTION THEREOF | HITACHI LTD | 1990-08-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178679-A1 | FUSED AROMATIC PTP-IB INHIBITORS | PTPRF, PTPRJ, PTPRCAP | AHR 1623/4885APEX1 3288/4885 |
| US-20230125359-A1 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | RAD51, UBE2D3, MDM2 | AHR 720/4885APEX1 79/4885 |
| US-20240217976-A2 | COMPOUND AND POLYMER COMPOUND CONTAINING THE COMPOUND | RAD51, MDM2, UBE2D3 | AHR 955/4885APEX1 80/4885 |
| US-20150045325-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | AHR 1497/4885APEX1 2862/4885 |
| US-20130281365-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | AHR 1497/4885APEX1 2862/4885 |
| US-20100022477-A1 | FUSED AROMATIC PTP-1B INHIBITORS | PTPRJ, PTPRF, PTPRCAP | AHR 1497/4885APEX1 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.